论文部分内容阅读
目的:评价妊娠期肝内胆汁淤积症(ICP)应用多联药物治疗的临床疗效。方法:随机将50例ICP患者分为两组,每组患者25例,分别给予思美泰及熊去氧胆酸治疗(对照组)和地塞米松联合思美泰及熊去氧胆酸治疗(试验组),对比两组治疗前及生产时肝功能(ALT、AST、TBA、TB、DB)改善情况、产后出血量及新生儿健康情况。结果:接受治疗前两组ALT、AST、TBA、TB及DB差异未见统计学意义(P>0.05),生产时试验组ALT、AST、TBA、TB及DB改善较对照组更为明显,差异有统计学意义(P<0.05),产后2周两组比较差异未见统计学意义(P>0.05)。同时试验组产后出血量明显低于对照组,且新生儿健康情况明显优于对照组,差异均有统计学意义(P<0.05)。结论:三联药物治疗ICP可显著提高治疗效果,改善产妇及新生儿的预后。
Objective: To evaluate the clinical effect of multi-drug treatment in intrahepatic cholestasis of pregnancy (ICP). Methods: Fifty patients with ICP were randomly divided into two groups, 25 patients in each group, treated with Smectite and ursodeoxycholic acid (control group) and dexamethasone combined with Smectite and ursodeoxycholic acid (Experimental group). The improvement of liver function (ALT, AST, TBA, TB, DB), postpartum hemorrhage and neonatal health before and during treatment were compared between two groups. Results: There was no significant difference in ALT, AST, TBA, TB and DB between the two groups before treatment (P> 0.05). The improvement of ALT, AST, TBA, TB and DB in the experimental group was more obvious than that in the control group There was statistical significance (P <0.05). There was no significant difference between the two groups in postpartum 2 weeks (P> 0.05). At the same time, the amount of postpartum hemorrhage in the experimental group was significantly lower than that in the control group, and the newborn’s health condition was significantly better than that in the control group. The difference was statistically significant (P <0.05). Conclusion: Triple therapy with ICP can significantly improve the therapeutic effect and improve the prognosis of maternal and newborn.